Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

Dragana Miletić; Marija Kraljević; Emir Sokolović; Majana Soče; Marijana Milović-Kovačević; Simonida Bobić; Timur Cerić; Stjepko Pleština; Semir Bešlija; Inga Marijanović

doi:10.12659/MSM.940356

02 June 2023: Clinical Research

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

Dragana Miletić ^1ADEF* , Marija Kraljević ^1ADEF , Emir Sokolović ^2CDE , Majana Soče ^3B , Marijana Milović-Kovačević ^4B , Simonida Bobić ^4B , Timur Cerić ^2ABDE , Stjepko Pleština ^3A , Semir Bešlija ^2AE , Inga Marijanović ^15ADE

DOI: 10.12659/MSM.940356

Med Sci Monit 2023; 29:e940356

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 7 Second-line progression-free survival (PFS) of patients with metastatic HER2-positive breast cancer in 4 oncology centers in high-income and upper-middle-income countries according to the different oncology clinics.

Back to the Article

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

Your Privacy